Bone Biologics Corp (BBLGW) Long-Term Debt Issuances (2013 - 2021)

Bone Biologics (BBLGW) has reported Long-Term Debt Issuances for 7 consecutive years, with $276706.0 the latest figure, recorded in Q3 2021.

• In Q3 2021, Long-Term Debt Issuances rose 269.97% year-over-year to $276706.0; the TTM figure through Dec 2024 stood at $845960.0 (changed N/A YoY), while the FY2024 annual figure was $1.8 million, changed N/A from the prior year.
• Long-Term Debt Issuances eased to $276706.0 in Q3 2021 per BBLGW's latest filing, from $569254.0 in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $2.0 million in Q1 2017 and bottomed at $74791.0 in Q3 2020.
• Historically, Long-Term Debt Issuances has averaged $497530.5 across 4 years, with a median of $276706.0 in 2021.
• Annual changes were most pronounced in 2020 — Long-Term Debt Issuances tumbled 92.34% — and 2021, when it jumped 643.15%.
• Bone Biologics' Long-Term Debt Issuances stood at $700000.0 in 2017, then tumbled by 82.86% to $120000.0 in 2019, then retreated by 6.15% to $112623.0 in 2020, then surged by 145.69% to $276706.0 in 2021.
• Business Quant data shows BBLGW's Long-Term Debt Issuances at $276706.0 in Q3 2021, $569254.0 in Q2 2021, and $209757.0 in Q1 2021.